The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“once weekly subcutaneous injection with semaglutide resulted in a marked and sustained weight loss of >15% in patients who are overweight or obese.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Hypertension and Cardiac Failure in its Various Forms
Gaddam, K. K., Verma, A., Thompson, M., Amin, R. R., & Ventura, H. O. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.005 · Cited by 35
Hypertension and diastolic heart failure
Gradman, A. H., & Wilson, J. T. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0061-5 · Cited by 35
Maning, J., Negussie, S., Clark, M. A., & Lymperopoulos, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.009 · Cited by 35
Cheng, Z., Zhang, M., Hu, J., Lin, J. M., Feng, X., Wang, S., Wang, T., Gao, E., Wang, H., & Sun, D. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.08.028 · Cited by 35
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
Cinti, F., Laborante, R., Cappannoli, L., Morciano, C., Gugliandolo, S., Pontecorvi, A., Burzotta, F., Donniacuo, M., Cappetta, D., Patti, G., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02767-9 · Cited by 38
Management of Heart Failure With Preserved Ejection Fraction: A Review
Nanayakkara, S., & Kaye, D. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.005 · Cited by 34
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 36
Self-citationAngiotensin II Receptor Blockers and Cancer Risk
Zhao, Y.-T., Li, P., Zhang, J.-Q., Wang, L., & Zhong, Y. (2016) · Medicine · doi:10.1097/md.0000000000003600 · Cited by 34
Fukuta, H., Goto, T., Wakami, K., & Ohte, N. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9637-0 · Cited by 34
Pouleur, A., Anker, S. D., Brito, D. A., Brosteanu, O., Hasenclever, D., Casadei, B., Edelmann, F., Filippatos, G. S., Gruson, D., Ikonomidis, I., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12306 · Cited by 34
Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach
Silverman, D. N., & Shah, S. J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0709-4 · Cited by 35
Angiotensin Type 1 Receptor Blockers in Heart Failure
Singh, K. D., & Karnik, S. S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190821152000 · Cited by 35
Juillière, Y., Selton‐Suty, C., Riant, E., Darracq, J.-P., Dellinger, A., Labarre, J., Druelle, J., Mulak, G., Danchin, N., & Patrick Jourdain, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.11.001 · Cited by 34
Yap, J. J. L., Sim, D., Lim, C. P., Chia, S. Y., Go, Y. Y., Jaufeerally, F. R., Sim, L. L., Liew, R., & Ching, C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.063 · Cited by 34
Fator de diferenciação de crescimento 15: um novo biomarcador em pacientes com disfunção diastólica?
Dinh, W., Füth, R., Lankisch, M., Heß, G., Zdunek, D., Scheffold, T., Kramer, F., Klein, R. M., Barroso, M. C., & Nickl, W. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011005000058 · Cited by 34
Datzmann, T., Fuchs, S., Andrée, D., Hohenstein, B., Schmitt, J. M., & Schindler, C. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.04.019 · Cited by 35
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.02.007 · Cited by 33
Self-citationCastiglione, V., Gentile, F., Ghionzoli, N., Chiriacò, M., Panichella, G., Aimo, A., Vergaro, G., Giannoni, A., Passino, C., & Emdin, M. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.23 · Cited by 35
Coles, A. H., Fisher, K. A., Darling, C. E., Yarzebski, J., McManus, D. D., Gore, J. M., Lessard, D., & Goldberg, R. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.06.017 · Cited by 33
Docherty, K. F., Bayés‐Genís, A., Butler, J., Coats, A. J. S., Drazner, M. H., Joyce, E., & Lam, C. S. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac113 · Cited by 40
The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study
Ezekowitz, J. A., Becher, H. H., Belenkie, I., Clark, A. M., Duff, H. J., Friedrich, M. G., Haykowsky, M. J., Howlett, J. G., Kassiri, Z., Kaul, P., et al. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-91 · Cited by 34
Gaasch, W. H., Delorey, D. E., Kueffer, F. J., & Zile, M. R. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.064 · Cited by 33
Self-citationAronson, D., Musallam, A., Lessick, J., Dabbah, S., Carasso, S., Hammerman, H., Reisner, S. A., Agmon, Y., & Mutlak, D. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.877340 · Cited by 33
Casado, J., Montero-Pérez-Barquero, M., Formiga, F., Carrera, M., Urrútia, A., Arévalo‐Lorido, J. C., & Pérez‐Calvo, J. I. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.06.003 · Cited by 32
Targeting heart failure with preserved ejection fraction: current status and future prospects
Kanwar, M. K., Walter, C. E., Clarke, M. M., & Aponte, M. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83662 · Cited by 32
Torres, W. M., Barlow, S. C., Moore, A. B., Freeburg, L., Hoenes, A., Doviak, H., Zile, M. R., Shazly, T. M., & Spinale, F. G. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.007 · Cited by 30
Self-citationBlood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Selvaraj, S., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Fang, J. C., Vardeny, O., Desai, A. S., Shah, S. J., Lam, C. S. P., Martínez, F. A., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.002 · Cited by 33
Self-citationZhou, J., Shi, H., Zhang, J., Lu, Y., Fu, M. L. X., Ge, J., & for the β-PRESERVE Study Investigators (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp193 · Cited by 32
Zhang, Y., Kilgore, M. L., Arora, T., Mujib, M. U., Ekundayo, O. J., Aban, I., Feller, M. A., Desai, R. V., Love, T. E., Allman, R. M., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.089 · Cited by 32
Diastolic heart failure: What we still don’t know
Tschöpe, C., & Lam, C. S. P. (2012) · Herz · doi:10.1007/s00059-012-3719-5 · Cited by 32
Patel, R. B., & Shah, S. J. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021136 · Cited by 31
Bachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
Li, Z., Chen, F., Wang, X., & Wang, C. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2784 · Cited by 31
Left Ventricular Stiffening as Therapeutic Target for Heart Failure With Preserved Ejection Fraction
Sakata, Y., Ohtani, T., Takeda, Y., Yamamoto, K., & Mano, T. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0214 · Cited by 31
Contemporary Strategies in the Diagnosis and Management of Heart Failure
Dunlay, S. M., Pereira, N. L., & Kushwaha, S. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.004 · Cited by 30
Shah, S. J. (2010) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0060-2 · Cited by 31
Elgendy, I. Y., Huo, T., Chik, V., Pepine, C. J., & Bavry, A. A. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu209 · Cited by 32
Dixon, D., Trivedi, A. D., & Shah, S. J. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9523-6 · Cited by 31
Hage, C., Bjerre, M., Frystyk, J., Gu, H. F., Brismar, K., Donal, E., Daubert, J., Linde, C. M., & Lund, L. H. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.02.041 · Cited by 35
Hyperkalaemia: aetiology, epidemiology, and clinical significance
Tromp, J., & van der Meer, P. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy028 · Cited by 31
Park, J. J., Choi, H., Hwang, I., Park, J., Park, J., & Cho, G. (2019) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.06.017 · Cited by 31
A new approach to the clinical subclassification of heart failure with preserved ejection fraction
Nouraei, H., & Rabkin, S. W. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.01.052 · Cited by 31
Myhre, P. L., Selvaraj, S., & Solomon, S. D. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000852 · Cited by 30
Recent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 35
Mishra, R., Yang, W. P., Roy, J. A., Anderson, A. H., Bansal, N., Chen, J., deFilippi, C. R., Delafontaine, P., Feldman, H. I., Kallem, R. R., et al. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002097 · Cited by 31
Heart Failure with Preserved Ejection Fraction
Altay, H., & Pehlivanoğlu, S. (2017) · InTech eBooks · doi:10.5772/66758 · Cited by 30
Serotonin 5-HT 2B Receptor in Cardiac Fibroblast Contributes to Cardiac Hypertrophy
Shyu, K. (2008) · Circulation Research · doi:10.1161/circresaha.108.191122 · Cited by 31
Exercise Training in Heart Failure With Preserved Ejection Fraction
Kitzman, D. W. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.024 · Cited by 31
The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype
Lindman, B. R. (2017) · Circulation · doi:10.1161/circulationaha.116.025957 · Cited by 31
Heart failure with preserved ejection fraction.
Rigolli, M., & WHALLEY, G. A. (2013) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2013.04.011 · Cited by 30
Khong, F. L., Zhang, Y., Edgley, A. J., Qi, W., Connelly, K. A., Woodman, O. L., Krum, H., & Kelly, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022777 · Cited by 30
Stavrakis, S., Pakala, A. V., Thadani, U., Thomas, J., & Chaudhry, M. Q. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318271c012 · Cited by 30
Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy
Gupta, A., Schiros, C. G., Gaddam, K. K., Aban, I., Denney, T. S., Lloyd, S. G., Oparil, S., Dell’Italia, L. J., Calhoun, D. A., & Gupta, H. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.83 · Cited by 30
Lymperopoulos, A., & Aukszi, B. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i3.200 · Cited by 30
Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
Nanayakkara, S., Patel, H. C., & Kaye, D. M. (2018) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546817751609 · Cited by 30
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
Farsang, C. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23468 · Cited by 30
Heart Failure with Normal Ejection Fraction
Tschöpe, C., & Westermann, D. (2009) · Herz · doi:10.1007/s00059-009-3197-6 · Cited by 30
Regional Differences in Heart Failure With Preserved Ejection Fraction Trials
Rossignol, P., & Zannad, F. M. (2014) · Circulation · doi:10.1161/circulationaha.114.013637 · Cited by 30
Lin, X., Wu, G., Wang, S., & Huang, J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10362-x · Cited by 32
Desai, N. R., Olewińska, E., Famulska, A., Rémuzat, C., François, C., & Folkerts, K. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10385-y · Cited by 36
Tromp, J., Kosiborod, M., Angermann, C. E., Collins, S. P., Teerlink, J. R., Ponikowski, P. P., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3218 · Cited by 35
Pană, M.-A., Boulmpou, A., İleri, Ç., Manzi, G., Golino, M., Ostojic, M., Galimzhanov, A. M., Busnatu, Ș., Mega, S., & Perone, F. (2025) · Medicina · doi:10.3390/medicina61020211 · Cited by 34
Heart Failure in Very Old Adults
Forman, D. E., Ahmed, A., & Fleg, J. L. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0163-7 · Cited by 29
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction
Oktay, A. A., & Shah, S. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0545-9 · Cited by 31
Meune, C., Wahbi, K., Duboc, D., & Weber, S. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410391667 · Cited by 29
Heart Failure as a Disruption of Dynamic Circulatory Homeostasis Mediated by the Brain
Kishi, T. (2016) · International Heart Journal · doi:10.1536/ihj.15-517 · Cited by 29
Ayme‐Dietrich, E., Marzak, H., Lawson, R., Mokni, W., Wendling, O., Combe, R., Becker, J., Fertak, L. E., Champy, M., Matz, R. L., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000695 · Cited by 29
Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
Lakhani, I., Leung, K. S. K., Tse, G., & Lee, A. P. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00874 · Cited by 29
Clark, H., Rana, R. H., Gow, J., Pearson, M. J., van der Touw, T., & Smart, N. A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10097-7 · Cited by 29
Wu, C., Wang, Y., Lee, J., Chang, S., Su, M.-Y. M., Yeh, H., Su, M., Chen, J., Chiang, F., Hwang, J., et al. (2013) · European Journal of Heart Failure · doi:10.1002/ejhf.33 · Cited by 29
Georgiopoulou, V. V., Kalogeropoulos, A. P., & Butler, J. (2012) · Drugs · doi:10.2165/11631100-000000000-00000 · Cited by 30
Gonzalez, G. E., Seropian, I. M., Krieger, M. L., Palleiro, J., Verrilli, M. A. L., Gironacci, M. M., Cavallero, S., Wilensky, L., Tomasi, V. H., Gelpi, R. J., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00498.2007 · Cited by 29
Xie, W., Zheng, F., Song, X., Zhong, B., & Li, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.010 · Cited by 28
Feuerstein, A., Bartels, I., Münch, M., Trippel, T. D., Lindhorst, R., Nolte, K., Herrmann‐Lingen, C., Halle, M., Duvinage, A., Düngen, H., et al. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12227 · Cited by 29
The Role of Vascular Calcification in Heart Failure and Cognitive Decline
Cheng, H., Wang, J., & Chen, C. (2017) · Pulse · doi:10.1159/000484941 · Cited by 29
Pedrinelli, R. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4800 · Cited by 29
Ostrominski, J. W., Lassen, M. C. H., Butt, J. H., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.012 · Cited by 34
Self-citationNogi, S., Fujita, S.-I., Okamoto, Y., Kizawa, S., Morita, H., Ito, T., Sakane, K., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00402.2015 · Cited by 28
Pufulete, M., Maishman, R., Dabner, L., Mohiuddin, S., Hollingworth, W., Rogers, C. A., Higgins, J. P. T., Dayer, M., Macleod, J., Purdy, S., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21400 · Cited by 26
Huang, W., Oliveira, R. K. F., Lei, H., Systrom, D. M., & Waxman, A. B. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.11.003 · Cited by 28
The contribution of comorbidities to mortality in hospitalized patients with heart failure
Riedel, O., Ohlmeier, C., Enders, D., Elsässer, A., Vizcaya, D., Michel, A., Eberhard, S., Schlothauer, N. I., Berg, J., & Garbe, E. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1210-x · Cited by 28
Kawano, H., Fujiwara, A., Kai, H., Kumagai, E., Okamoto, R., Shibata, R., Ohtsubo, T., Tamura, K., Maemura, K., & Arima, H. (2019) · Hypertension Research · doi:10.1038/s41440-019-0216-8 · Cited by 28
TORII, Y., Kusunose, K., Yamada, H., Nishio, S., Hirata, Y., Amano, R., Yamao, M., Zheng, R., Saijo, Y., Yamada, N., et al. (2019) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.06.006 · Cited by 28
Escher, A., Choi, Y. J., Callaghan, F. M., Thamsen, B., Kertzscher, U., Schweiger, M., Hübler, M., & Granegger, M. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02492-2 · Cited by 28
Hoes, A. W., Voors, A., Rutten, F. H., van Lieshout, J., Janssen, P. G. H., & Walma, E. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_24 · Cited by 28
Nie, D., Xiong, B., Qian, J., Rong, S., Yao, Y., & Huang, J. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.10.012 · Cited by 29
Bojer, A. S., Soerensen, M. H., Gæde, P., Myerson, S. G., & Madsen, P. L. (2021) · Diagnostics · doi:10.3390/diagnostics11071282 · Cited by 28
Severino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 30
Sipahi, İ. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263461 · Cited by 30
Harrington, J., Petrie, M. C., Anker, S. D., Bhatt, D. L., Jones, W. S., Udell, J. A., Hernandez, A. F., & Butler, J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2847 · Cited by 28
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 30
Yano, Y., Hoshide, S., Tamaki, N., Nagata, M., Sasaki, K., Kanemaru, Y., Shimada, K., & Kario, K. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310390404 · Cited by 29
Nishihara, T., Yamamoto, E., Sueta, D., Fujisue, K., Usuku, H., Oike, F., Takae, M., Arima, Y., Araki, S., Takashio, S., et al. (2019) · Medicine · doi:10.1097/md.0000000000017069 · Cited by 28
Kristensen, S. L., Jhund, P. S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Michel Komajda, N., Cleland, J. G. F., Carson, P. E., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.01.014 · Cited by 28
Self-citationZile, M. R., & Gaasch, W. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.068 · Cited by 28
Self-citationGharagozloo, K., Mehdizadeh, M., Heckman, G. A., Rose, R. A., Howlett, J. G., Howlett, S. E., & Nattel, S. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.006 · Cited by 32
Central Adiposity or Hypertension
Packer, M., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.036 · Cited by 30
Current Challenges in the Management of Heart Failure
Michel Komajda, N. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0368 · Cited by 27
Nishihara, T., Tokitsu, T., Sueta, D., Takae, M., Oike, F., Fujisue, K., Usuku, H., Takashio, S., Hanatani, S., Kanazawa, H., et al. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy101 · Cited by 27
Metadata
- Authors
- Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., & Ptaszynska, A.
- Affiliations
- San Francisco VA Medical Center (US)
- Georgetown University (US)
- University of Glasgow (GB)
- Hamilton Health Sciences (CA)
- Medical University of South Carolina (US)
- University of Wisconsin–Madison (US)
- Bristol-Myers Squibb (United States) (US)
- Sanofi (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2456-2467
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068519950
- Cited by
- 1,960
- References
- 37
- Citations by year
- 2026: 61 · 2025: 72 · 2024: 92 · 2023: 94 · 2022: 128 · 2021: 120 · 2020: 123 · 2019: 118 · 2018: 117 · 2017: 138 · 2016: 105 · 2015: 127 · 2014: 119 · 2013: 122 · 2012: 109
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- irbesartan, heart failure with preserved ejection fraction, angiotensin receptor blockers, cardiovascular mortality, cardiovascular hospitalization, heart failure hospitalization, quality of life, elderly patients
- MeSH terms
- Irbesartan, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiovascular Diseases, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Tetrazoles, Proportional Hazards Models, Treatment Failure, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
